Introduction
============

Chronic pancreatitis (CP) is associated with pancreatic duct stones in 50 % to 90 % of patients [@JR1436-1] . These stones may occur in the main pancreatic duct (MPD) or side branches (SB), and contribute to increased intraductal and parenchymal pressure [@JR1436-1] [@JR1436-2] [@JR1436-3] . The composition of pancreatic stones may include an inner nidus of nickel, iron, and chromium surrounded by successive layers of calcium carbonate. These constituents contribute to pancreatic stones being harder than bile duct stones, making endoscopic treatment often challenging, especially when combined with ductal strictures and angulations [@JR1436-1] [@JR1436-3] .

The goal of therapy in CP is symptom control and pain relief, with the aim of decompressing an obstructed main pancreatic duct and/or removal of obstructing stones. Historically, treatment has been endoscopic or surgical, with endoscopic treatment consisting of ERCP with pancreatic sphincterotomy/endoscopic papillary balloon dilation (EPBD), stone extraction using a retrieval basket and/or retrieval balloon and stent placement. Surgical treatment usually involves resection and drainage. Prior studies have shown that both treatments are effective although surgery is longer lasting [@JR1436-2] [@JR1436-3] . Given the challenges in endoscopic treatment, Extracorporeal shockwave lithotripsy (ESWL) has been considered lately as the cornerstone treatment modality in symptomatic CP. Multiple studies have shown MPD clearance after ESWL, alone or in combination with ERCP, of 59 % to 80 % and long-term pain relief of 60 % to 90 % [@JR1436-1] [@JR1436-3] [@JR1436-4] .

Per-oral pancreatoscopy (POP) enables direct visualization of the pancreatic duct. Although it has been available since the 1990s, it was not popular given technical difficulties, the requirement for two operators, and poor imaging quality. With the introduction of the single-operator cholangiopancreatoscopy system (SOCP) (SpyGlass; Boston Scientific, Natick, Massachusetts, United States) in 2007, the requirement for two operators was solved [@JR1436-5] [@JR1436-6] . Nevertheless, it was underutilized due to suboptimal fiber optic imaging [@JR1436-7] . The digital version of SOC (D-SOCP) (SpyGlass DS; Boston Scientific), available since February 2015, significantly improved image quality compared to the prior system, possibly increasing its diagnostic and therapeutic capabilities [@JR1436-5] [@JR1436-6] . Electrohydraulic lithotripsy (EHL) or laser lithotripsy (LL) can be used during SOCP to achieve stone fragmentation, enabling complete ductal clearance during ERCP in a safe and efficient manner [@JR1436-1] [@JR1436-6] [@JR1436-8] [@JR1436-9] . Our group previously reported the largest cohort of patients with difficult bile duct stones treated with D-SOC with EHL/LL with 97 % efficacy in clearing the bile duct [@JR1436-6] . Presently, POP with EHL/LL is used mainly as a rescue therapy after failure of ESWL.

A few studies with small sample sizes or using non-digital pancreatoscopes have assessed the performance of EHL or LL in treatment of pancreatic stones, with a reported efficacy of 40 % to 100 % [@JR1436-1] [@JR1436-10] [@JR1436-11] [@JR1436-12] . The new digital version of the SOP with improved image quality possibly aids stone fragmentation using the available lithotripsy devices. The primary aim of this study was to assess technical success, defined as pancreatic duct clearance, in patients with chronic pancreatitis and MPD stones. Secondary aims were to assess the safety of D-SOP with EHL or LL and to compare the effectiveness of EHL vs. LL in the largest cohort of patients with obstructing pancreatic stones to date.

. Patients and methods
======================

###### 

  **Video 1**  DSOP with LL for treatment of MPD stone.

###### 

  **Video 2**  DSOP with EHL for treatment of MPD stone.

This was a retrospective, international, multicenter study including 17 tertiary centers (14 from the United States, 3 from Europe). Institutional Review Board approval was obtained at all institutions. Medical records were assessed to identify all consecutive adult patients (\> 18 years) who underwent D-SOP using either EHL or LL for management of obstructing pancreatic duct stones from February 2015 to September 2017.

The study included patients with symptomatic pancreatic stones, most of whom had prior attempts at stone clearance using standard ERCP techniques and/or ESWL. Intraductal stones were diagnosed by abdominal cross-sectional imaging or prior ERCP. Procedures done with the older version of SOP or other types of cholangiopancreatoscopes were excluded, as were all cases of D-SOP without EHL/LL. All procedures were performed under general anesthesia or propofol deep sedation. Procedure time was defined as the time between duodenoscope scope-in and scope-out. Patients were admitted to hospital for a planned 23-hour observation period after the index D-SOP. Nevertheless, when clinically appropriate, patients were discharged after a 1- to 2-hour period of observation. When the index D-SOP EHL/LL yielded partial or failed stone clearance, repeated D-SOP was attempted until complete clearance was achieved. The endoscopist determined stone clearance based on final pancreatogram or D-SOP at the time of the procedure.

The D-SOP (Spyglass DS, Boston Scientific) is a single-use 10.8 French (F) scope with four-way tip maneuverability, dedicated irrigation and aspiration channels, and one 1.2-mm working channel. It has enhanced visualization with a digital sensor [@JR1436-4] [@JR1436-5] [@JR1436-7] .

Several lasers have been developed. Laser light at a particular wavelength is focused on the surface of the stone to induce wave-mediated fragmentation [@JR1436-1] . In this study, the VersaPulse P20, Slim line 365-µm fiber Holmium laser (Ho:YAG) (Lumenis Inc., San Jose, California, United States) was used. The power setting was maximum 20 W (starting at 1 J and 10 Hz then rising to 2.5 J × 8 Hz), in bursts of 5 seconds. Stone fragments were retrieved by standard techniques ( [Fig. 1](#FI1436-1){ref-type="fig"} ) ( [Supplemental Video 1](#ME1436-1){ref-type="media"} ).

![ 63-year-old female with history of alcohol induced chronic pancreatitis. Patient has recurrent post prandial abdominal pain. CT scan showed dilated MPD with stones. **a** ERCP showing a dilated, tortuous MPD with multiple filling defects at the genu/body. **b** Intraductal pancreatic stone seen on pancreatoscopy. **c** Ho:YAG lasers' probe green light on the surface of the stone. **d** Final ERCP pancreatogram showing decompressed MPD without filling defects.](10-1055-a-0889-7743-i1436ei1){#FI1436-1}

EHL is a bipolar 1.9 F probe that discharges sparks with the aid of a charge generator (AUTOLITH, Northgate Technologies Inc., Illinois, United States) in an aqueous medium (normal saline). The probe is positioned 1 to 2 mm from the stone. The spark produced under the saline medium generates high-frequency hydraulic pressure waves, absorbed by nearby stones resulting in their fragmentation. Shock waves are delivered in brief pulses, ranging from a single discharge to continuous firing [@JR1436-1] [@JR1436-5] . The stone fragments were retrieved by conventional ERCP techniques. The power settings in the generator ranged between low/medium/high (50 -- 100 %) and delivered over 1- to 2-second bursts ( [Fig. 2](#FI1436-2){ref-type="fig"} ) ( [Supplemental Video 2](#ME1436-2){ref-type="media"} ).

![ 33-year-old male with recurrent acute on chronic pancreatitis secondary to heterozygous SPINK1 N34S mutation. On CT scan, a stone located in the MPD at the level of the pancreatic body with upstream ductal dilation was noted. **a** ERCP showed a mildly dilated and tortuous MPD with side branches widening. The distal body/tail is not visualized despite high quality pancreatogram and attempts to pass the wire distally were unsuccessful. **b** The pancreatoscope was advanced over the wire to the area that was not well visualized. **c** A round stone was seen on pancreatoscopy. EHL probe advanced. **d** Fragments of the stone post lithotripsy.](10-1055-a-0889-7743-i1436ei2){#FI1436-2}

The type of lithotripsy device used in the current study was chosen solely based on endoscopist preference and the center's availability.

Outcomes and definitions
------------------------

The primary study outcome was rate of technical success, defined as complete pancreatic duct clearance. Safety of D-SOP using either EHL or LL was defined by the rate and severity of adverse events (AEs) as graded per the ASGE lexicon (mild, moderate, severe, fatal) [@JR1436-13] . Other outcomes included clinical success (defined by resolution or improvement of symptoms), number of D-SOP with EHL/LL sessions needed to clear the MPD, need for other therapies (ESWL or surgery), incomplete stone removal/stone recurrence and procedure time. Comparison of outcomes between EHL vs. LL was also assessed.

Statistical analysis
--------------------

Descriptive statistics was presented as frequencies (%) for categorical variables and mean ± standard deviation (SD) or median (interquartile range \[IQR\]) for continuous variables. Chi-square test and Fisher's exact test were used to compare categorical data while Student's *t* -test and Wilcoxon rank-sum test were used for continuous data, as appropriate. A *P* value ≤ 0.05 was considered statistically significant. Logistic regression analysis was performed to identify factors associated with the need for more than one session of D-SOP with EHL/LL. Statistical analysis was performed using Stata software (Stata version 14.1, College Station, Texas, United States).

Results
=======

A total of 109 patients (71 % male, mean age 54.7 ± 15.0 years) underwent D-SOP with EHL or LL for pancreatic ductal stones. Most common presenting symptoms were abdominal pain (96.3 %) and/or weight loss (51.4 %). Diabetes was present in 48.6 %; 74.3 % were on pancreatic enzymes and 74.3 % on opioids. Most patients (88.1 %) had prior ERCP attempts and a minority (11 %) prior ESWL session(s) with failed ductal clearance. The most frequent prior intervention was stone extraction using a retrieval balloon (73.4 %). Seventy-four patients (67.9 %) had a plastic pancreatic stent placed during a prior failed ERCP. Mean MPD diameter by prior imaging was 9.2 ± 3.5 mm ( [Table 1](#TB1436-1){ref-type="table"} ).

###### Patient baseline characteristics.

                                                       **Total (N = 109)**   **EHL (N = 59)**   **LL (N = 50)**   ***P* value**
  ---------------------------------------------------- --------------------- ------------------ ----------------- ---------------
  **Female sex; n (%)**                                 32 (29.4)            23 (39)             9 (18)              0.02
  **Mean age (mean ± SD)**                              54.7 ± 15            56 ± 16            53 ± 13              0.3
  **Symptoms**                                                                                                    
  Abdominal pain; n (%)                                105 (96.3)            56 (94.9)          49 (98)              0.62
  Weight loss; n (%)                                    56 (51.4)            16 (27.1)          40 (80)            \< 0.001
  **On pancreatic enzymes; n (%)**                      81 (74.3)            37 (62.7)          44 (88)              0.003
  **Opioid use; n (%)**                                 81 (74.3)            39 (66.1)          42 (84)              0.05
  **Diabetes; n (%)**                                   53 (48.6)            20 (33.9)          33 (66)              0.001
  **Exocrine pancreatic insufficiency; n (%)**          46 (42.2)            15 (25.4)          31 (62)            \< 0.001
  **Prior ESWL**                                        12 (11)              10 (16.9)           2 (4)               0.03
  **Patients from community (not center)**              68 (62.4)            26 (44.1)          42 (84)            \< 0.001
  **Prior ERCP with failed stone extraction; n (%)**    96 (88.1)            46 (78)            50 (100)           \< 0.001
  **Prior interventions for stone removal**                                                                       
  Balloon extraction; n (%)                             80 (73.4)            36 (61)            44 (88)              0.001
  Retrieval basket; n (%)                               13 (11.9)             8 (13.6)           5 (10)              0.57
  EHL; n (%)                                            10 (9.2)              4 (6.8)            6 (12)              0.51
  LL; n (%)                                              6 (5.5)              0 (0)              6 (12)              0.008
  Prior surgery; n (%)                                   1 (0.9)              1 (1.7)            0 (0.0)             1
  **Indwelling pancreatic stent; n (%)**                74 (67.9)            42 (71.2)          32 (64)              0.54
  **Main pancreatic duct size; (mean ± SD) (mm)**        9.2 + 3.5            8.3 + 2.9         10.1 + 3.9           0.008
  **Stone location**                                      0.16                                                    
  Head; n (%)                                           54 (49.5)            35 (59.3)          19 (38)           
  Neck; n (%)                                           23 (21.1)            10 (16.9)          13 (26)           
  Body; n (%)                                           15 (13.8)             6 (10.2)           9 (18)           
  Tail; n (%)                                            6 (5.5)              4 (6.8)            2 (4)            
  Multifocal; n (%)                                     11 (10.1)             4 (6.8)            7 (14)           
  **Stone size (largest)**                                0.04                                                    
   \< 10 mm; n (%)                                      62 (56.9)            40 (67.8)          22 (44)           
  10 -- 19 mm; n (%)                                    32 (29.4)            13 (22)            19 (38)           
   \> 20 mm; n (%)                                      15 (13.8)             6 (10.2)           9 (18)           
  **More than 3 stones in MPD; n (%)**                  47 (43.1)            30 (50.8)          17 (34)              0.077
  **Stone impaction; n (%)**                            67 (61.5)            26 (44.1)          41 (82)            \< 0.001
  **Main pancreatic duct stricture; n (%)**             85 (78)              39 (66.1)          46 (92)              0.001
  **Devices used for stone extraction**                   0.02                                                    
  Extraction balloon                                    91 (83.5)            44 (74.6)          47 (94)           
  Retrieval basket                                       5 (4.6)              5 (8.5)            0 (0)            
  Other                                                  2 (1.8)              2 (3.4)            0 (0)            
  Balloon + Basket                                       7 (6.4)              4 (6.8)            3 (6)            
  None                                                   4 (3.7)              4 (6.8)            0 (0)            

EHL, electrohydraulic lithotripsy; LL, laser lithotripsy; SD, standard deviation; ERCP, endoscopic retrograde cholangiopancreatography; MPD, main pancreatic duct

During the index D-SOP, all patients had successful MPD cannulation with the D-SOP. Image quality of stone visualization was reported as excellent in 67.9 % of cases and good in 30.3%. In two cases (1.8 %), visualization was reported as poor, with stones located in the MPD and side branches. The majority of stones were located in the head of pancreas (HOP) (49.5 %), followed by the neck/genu (21.1 %), body (13.8 %), tail (5.5 %), and 10.1 % were multifocal. Almost half of the cohort had more than three stones (43.2 %). Most stones (56.9 %) measured between 1 and 9 mm and 61.5 % were impacted. Most patients (78 %) had a downstream MPD stricture, the majority (87.1 %) of whom required stricture dilation to perform lithotripsy. After EHL or LL, the most common device used for stone extraction was the extraction balloon (83.5 %). Stents were placed after D-SOP in 98.2 % of patients. Mean procedure time (available in 78 % of patients) was 62.8 ± 23 minutes ( [Table 1](#TB1436-1){ref-type="table"} ).

Outcomes
--------

Complete ductal clearance using EHL/LL (technical success) was achieved in 89.9 % of patients, and in 73.5 % was accomplished in a single session ( [Table 2](#TB1436-2){ref-type="table"} ). Overall, success rates were similar among tertiary centers participating in this study. Half of patients needing more than one session had more than three stones (15/26), and stones were larger than 10 mm in 53.8 % (14/26). Moreover, 81 % of these patients (21/26) had a downstream stricture (i. e. between the ampulla and the stone). Eleven patients (10.1 %) failed DSOP and were treated with surgery (n = 1), ESWL alone (n = 6), combined treatment with ESWL/D-SOP EHL (n = 1) and other (n = 3) (ERCP/balloon sweep and stenting n = 2, awaiting treatment n = 1). Reported reasons for technical failure were: failed stone fragmentation (n = 3), failure to advance EHL probe to the site of the stone (n = 3), failure to advance the D-SOP due to angulation/tight stricture (n = 3) and unspecified reason (n = 2). Of the 11 patients with technical failure, three were attributed to failure of stone fragmentation by EHL. There were no failures of fragmentation in the LL group. Patients with technical failure had more than three stones (8/11), impacted stones (7/11) and a downstream stricture (6/11). Of the 11 patients with technical failure, one required surgery (Puestow procedure). This patient had more than three ductal stones, impacted stones, and a downstream stricture. Clinical success was achieved in 88.4 % of the patients.

###### Procedure outcomes.

                                                                                **Total (N = 109)**   **EHL (N = 59)**                                    **LL (N = 50)**                                      ***P* value**
  ----------------------------------------------------------------------------- --------------------- --------------------------------------------------- ---------------------------------------------------- ---------------
  **Technical success (pancreatic duct clearance); n (%)**                       98 (89.9)             48/51 [1](#FN1436-1){ref-type="table-fn"} (94.1)    50 (100)                                               0.243
  **Clinical Success; n (%), n = 95**                                            84 (88.4)             40 (88.9)                                           44 (88)                                                1
  **Number of EHL/LL sessions to clear pancreatic duct; n (%) (n = 98)**           0.5                                                                                                                         
  1                                                                              72 (73.5)             37 (77.1)                                           35 (70)                                             
  2 -- 3                                                                         23 (23.5)              9 (18.8)                                           14 (28)                                             
  More than 3                                                                     3 (3.1)               2 (4.2)                                             1 (2.0)                                            
  **Number of additional ERCPs for dilation/removing stents; n (%) (n = 90)**    \< 0.001                                                                                                                      
  None                                                                           12 (13.3)             12 (27.3)                                            0 (0.0)                                            
  1                                                                              52 (57.8)             19 (43.2)                                           33 (71.7)                                           
  2 -- 3                                                                         17 (18.9)              8 (18.2)                                            9 (19.6)                                           
  More than 3                                                                     9 (10)                5 (11.4)                                            4 (8.7)                                            
  **Stone recurrence; n (%) (n = 89)**                                            9 (10.1)              6 (14)                                              3 (6.5)                                               0.3
  **Management of stone recurrence (n = 9)**                                       0.36                                                                                                                        
  Balloon/basket; n (%)                                                           4 (44.4)              3 (50)                                              1 (33.3)                                           
  Cholangioscopy with EHL/LL; n (%)                                               1 (11.1)              1 (16.7)                                            0 (0)                                              
  ESWL; n (%)                                                                     1 (11.1)              0 (0)                                               1 (33.3)                                           
  Other; n (%)                                                                    1 (11.1)              0 (0)                                               1 (33.3)                                           
  None; n (%)                                                                     2 (22.2)              2 (33.3)                                            0 (0)                                              
  **Procedure time (min) (mean ± SD) (n = 85)**                                  62.8 + 23             74.4 ± 25.5                                         53.8 ± 16.2                                          \< 0.001
  **Number of patients with adverse events; n (%) (n = 11)**                     11 (10.1)              5 (8.5)                                             6 (12)                                                0.54
  **Median follow up time; days median (IQR)**                                  210 (68 -- 387)       157 (63 -- 353)                                     291 (141 -- 410)                                        0.005
  **Median time to recurrence; days (IQR) (n = 9)**                             105 (85 -- 471.5)      91 (76.25 -- 205.5)                                448 (105 --  [2](#FN1436-2){ref-type="table-fn"} )      0.5

EHL, electrohydraulic lithotripsy; LL, laser lithotripsy; ESWL, extracorporeal shockwave lithotripsy; SD, standard deviation.

Eight technical failures were due to reasons not specific to the EHL procedure per se and thus were excluded from the comparison of EHL vs LL in technical success.

There were only three recurrences. There is no interquartile range.

Fourteen adverse events (AEs) occurred in 11 patients (10.1%) including five pancreatitis, one MPD perforation, two bleeding, three fever and three abdominal pain without pancreatitis. These were rated as mild (n = 12, 85.7 %) and moderate (n = 2, 14.3 %), per ASGE lexicon. Ten patients (10/11) with AEs were admitted to the hospital. Most were treated conservatively with intravenous fluids, pain medication, and antibiotics, while five (5/11) were treated endoscopically with repeated ERCP and stent placement/exchange.

Predictors of outcomes
----------------------

Patients with more than three stones were more likely to have technical failure compared to those with less than three stones (17 % vs. 4.8 %, *P*  = 0.04). Similarly, patients with more than three stones were more likely to need more than one D-SOP EHL/LL session (38.5 % vs. 18.6 %, *P*  = 0.03). Multivariable analysis was not possible for technical failure due to the small number of events (n = 11). On the other hand, the only factor associated with the need for more than one session of D-SOP EHL/LL was having more than three ductal stones (OR 2.94, 95 % CI 1.13 -- 7.65), independently to the type of procedure (EHL vs. LL) and the age of the patient ( [Table 3](#TB1436-3){ref-type="table"} ).

###### Factors associated with the need of more than one DSOP with EHL/LL.

  Factors                     More than one D-SOP with EHL/LL (n = 26)   
  --------------------------- ------------------------------------------ ------
  EHL vs. LL                  0.64 (0.24 -- 1.67)                        0.36
  More than 3 ductal stones   2.94 (1.13 -- 7.65)                        0.04
  Age \> 55 years             0.42 (0.16 -- 1.09)                        0.08

EHL, electrohydraulic lithotripsy; LL, laser lithotripsy

Incomplete stone removal/recurrent stones
-----------------------------------------

Median follow-up time was 210 days \[IQR:68 -- 387\]. Patients with technical failure or those lost to follow-up were not included in this aspect of the analysis (20/109). After the index D-SOP EHL/LL, 86.7 % required at least an additional ERCP for stent removal/stent replacement and/or stricture dilation, and 13.4 % are waiting for a follow-up ERCP. Incomplete stone clearance/recurrent stones was seen in nine of 89 patients (10 %) after a median follow-up time of 105 days \[IQR:85 -- 471.5\]. Most of these patients had more than three stones and stone location was in the neck/genu, body, tail or multifocal (6/9).

Management of incomplete stone removal/ recurrent stones was performed with ERCP with extraction balloon (n = 4,44.4 %), repeated D-SOC with EHL/LL (n = 1,11.1 %), ESWL (n = 1,11.1 %), no treatment/expectant conduct (n = 2,22.2 %) and in one patient (11.1 %) treatment was not specified ( [Table 2](#TB1436-2){ref-type="table"} ).

EHL vs. LL
----------

Technical success was higher in the LL group (100 % vs. 94.1 %, *P*  = 0.243), although the difference was not significant. EHL procedures were significantly longer than those where LL was utilized (74.4 ± 25.5 min. vs. 53.8 ± 16.2 min, *P*  \< 0.001). On the other hand, the number of patients with AEs were not significantly different between the two groups (8.5 % vs 12 %, *P*  = 0.54). Moreover, in both groups, most patients needed one session to achieve MPD clearance (70.0 % vs. 77.1 %, *P*  = 0.49) and clinical success was similar as well (88 vs 88.9 %, *P*  = 1) ( [Table2](#TB1436-2){ref-type="table"} ).

Discussion
==========

Endoscopic management of pancreatic ductal stones can be challenging, due to stone size, density, and location. Small and floating calculi less than 5 mm can be extracted by standard techniques of ERCP with pancreatic sphincterotomy followed by balloon trawl or basket. Stones greater than 5 mm are often impacted and difficult to extract using standard techniques [@JR1436-3] . Reported rates of stone clearance using the basket have been as low as 9 % [@JR1436-3] [@JR1436-14] . Larger, impacted pancreatic stones require pre-extraction fragmentation using ESWL or other lithotripsy method, EPBD or surgical procedures. Factors that decrease the rate of endoscopic clearance include surgically altered anatomy, strictures, ductal angulation, and impacted stones [@JR1436-1] . ESWL alone or in combination with ERCP is reported to have an efficacy in clearing pancreatic stones of 59 % to 80 % [@JR1436-1] . Nevertheless, there are no definitive data on the number of sessions needed, and a subsequent ERCP is often performed after the last session to clear stone fragments, treat strictures, and place a stent, incurring additional costs. The rate of AEs of ESWL has been reported between 5.8 % and 6.7 % [@JR1436-1] [@JR1436-2] . Complications include pain and ecchymosis at the site of shockwave, abdominal pain, and fever. Rare AEs include perirenal hematoma, biliary obstruction, splenic rupture, bowel perforation, liver trauma, and necrotizing pancreatitis [@JR1436-1] [@JR1436-2] . Moreover, ESWL units are not typically within the endoscopy unit, requiring inter-departmental referrals, potentially delaying therapy.

D-SOC EHL/LL has been reported to be highly effective and safe in treating difficult bile duct stones [@JR1436-6] and previous small studies/case reports using POP in management of pancreatic stones have shown acceptable rates of success and safety [@JR1436-7] [@JR1436-10] [@JR1436-12] . The introduction of the D-SOC has improved the ease of SOC and markedly improved image quality. These have led to a greater utilization of EHL or LL in the ERCP armamentarium for management of difficult biliary and now pancreatic stones.

The largest study to date on SOP-LL in management of pancreatic stones was published by Atwell et al [@JR1436-12] ; a retrospective multicenter study including 28 patients, with 79 % complete ductal clearance and 11 % partial stone clearance rate. Stone clearance was achieved in one session in 61 % of patients and AEs were noted in 29 % of patients (post-ERCP pancreatitis and abdominal pain). A median of two stones sized 15 mm were identified in the head (32 %), neck (11 %), body (32 %), tail (4%), or multifocal (21 %); stone clearance was greater when stones were located in the head (92 %) compared to the tail (67 %). Main limitations of the study were small number of patients included and lack of information regarding reasons of prior ERCP or ESWL failures.

A systematic review performed by Beyna et al [@JR1436-1] , assessed the efficacy and safety of POP-guided EHL and LL in pancreatic stones, including both SOP versions (DS and Legacy) and other types of pancreatoscopes, with a total of 87 patients. The rate of successful ductal clearance was 43 % to 100 % with 0 % to 13.5 % AEs. Limitations were the heterogeneity of the studies and the variation in the type of pancreatoscopes.

Our multicenter study is the largest to date on use of D-SOP with EHL or LL in management of pancreatic stones, showing high efficacy and safety. Ductal clearance was seen in 89.9 % of patients, and in 73.5 % was achieved in a single session. Clinical success was seen in 88.4 % of patients. AEs were seen in 10.1 % of patients, the majority of which were pancreatitis (n = 5), bleeding (n = 3) and abdominal pain (n = 3), and managed conservatively in the majority of cases. When comparing EHL to LL, most outcomes were similar except for procedure time, which was longer in the EHL group, with statistical significance (74.4min vs. 53.8 min, *P*  \< 0.001). Pancreatic stones are often harder than bile duct stones (i.e Hounsfield index \> 2000 HU). The advantage of LL over EHL in terms of rate of success and requiring less procedure time theoretically could be explained by the ability of LL to fragment denser stones [@JR1436-10] [@JR1436-12] . Nevertheless, it is worth noting that LL technology is more expensive than EHL. Moreover, we need larger studies to validate our results. Regarding AEs, both techniques have similar AEs profiles, more frequent when compared to cholangioscopy and lithotripsy, mainly due to the higher risk of post ERCP pancreatitis, which is similar to risk of pancreatitis after standard pancreatic ERCP techniques (7 -- 15 %). Independently of the chosen lithotripsy technique, it is important to avoid long periods of pancreatic duct exposure to high energy levels in a single session, given the risk of thermal injury to the ductal wall.

Limitations of this study are its retrospective nature, introducing possible selection bias. Although we collected information about prior procedures before D-SOP-EHL/LL, the choice of first-line treatment of pancreatic stones varies among centers and future randomized controlled trials comparing conventional ERCP techniques to ESWL and D-SOP EHL/LL are needed to clearly define the exact role and timing of this technique. Also, there was lack of information regarding the reasons for ERCP/ESWL failures. Both groups differed in baseline characteristics which could affect the observed differences in outcomes. In addition, there were no objective measurements to assess pain or other symptoms before and after the procedure, making it difficult to accurately define the effect of D-SOP EHL/LL on symptom resolution. Even though our analysis showed that there are certain factors that could be associated with failure of D-SOP, the low number of patients with technical failure (n = 11) and the fact that there were no LL failures did not provide enough power to identify significant factors by multivariable analysis. Nevertheless, to our knowledge, this is the largest multicenter study on D-SOP with EHL/LL to date, involving 17 tertiary institutions. Our results may only be applicable to tertiary centers with high experience in chronic pancreatitis and D-SOP. Additionally, given the costs of these technologies, cost-effectiveness analysis comparing both techniques to ESWL and surgery is warranted.

Conclusion
==========

In conclusion, D-SOP with either EHL or LL may represent an efficient, safe, and minimally invasive alternative to ESWL and surgical approaches in management of obstructing pancreatic ductal stones. When comparing both techniques, they have similar efficacy and safety profile.
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